Overexpression of endothelial nitric oxide synthase and mitochondrial superoxide dismutase in the rostral ventrolateralmedulla in central cardiovascular regulation

• Main Authors: Ling-chang Kung, 孔令璋
• Other Authors: A. Y. W. Chang
• Format: Others
• Language: zh-TW
• Published: 2005
• Online Access: http://ndltd.ncl.edu.tw/handle/19194578630930402715

碩士 === 國立中山大學 === 生物科學系研究所 === 94 === The dissection of etiology of hypertension is a medical imperative. In the central nervous system, rostral ventral lateral medulla (RVLM) plays an essential role in the maintenance of arterial pressure and heart rate through tonic activation of the sympathetic vasomotor activity and regulation of baroreflex response. Oxidative stress of an enhanced cellular content of the reactive oxygen species, in particular the superoxide anion (O2-), has been implicated in hypertension. Superoxide dismutase (SOD) is one of the most important defense enzymes against the oxidative stress through catalysis of O2- into O2 and H2O2. SOD treatment has been demonstrated to decrease arterial pressure. Moreover, in addition to its peripheral vasodilatory effect, nitric oxide (NO) plays an active role in central regulation of arterial pressure and heart rate via modulation of the autonomic system. In the RVLM, both O2- and NO have been demonstrated to be involved in hypertension. Interactions between these two molecules, however, are not understood. The aims of this study are therefore to establish the significance of O2- and NO in the RVLM on blood pressure regulation in hypertension and to examine whether O2- interacts with NO to participate in the pathogenesis of hypertension. To examine their long term effects on mean systemic arterial pressure (MSAP) and heart rate (HR), SOD and/or NO was over-expressed by microinjection of the adenoviral vectors encoding the endothelial NO synthase (AdeNOS) and/or mitochondrial SOD (AdSOD2) into RVLM of the normotensive Wistar-Kyoto (WKY) rats or the spontaneously hypertensive rats (SHR). I found that microinjection of AdeNOS in the RVLM of SHR or WKY rats significantly decreased MSAP or HR that lasted for around 10 days postinjection. The hypotensive effect of AdeNOS was significantly greater in SHR than WKY rats. The AdeNOS-promoted hypotension in SHR, but not WKY rats, was followed by a rebound hypertension, detected in 28 days after the gene transfer. In the AdeSOD2-treated animals, I found a significant decrease in the MSAP in SHR, but not WKY rats, that lasted for about 7 days postinjection. On the other hand, no change in HR was detected in either SHR or WKY rats after the AdSOD2 gene transfer into the RVLM. In animals that received co-microinjection into the bilateral RVLM of AdeNOS and AdSOD2, there was a further prolonged decrease in MSAP or HR in SHR. The rebound hypertension observed in the AdeNOS-treated SHR was reversed to hypotension in the AdeNOS+AdSOD2-treated SHR. There was no difference in the hypotensive or bradycardiac effects in WKY rats that received the AdeNOS+AdSOD2 or AdeNOS gene transfer. Together these results suggest that (1) NO in RVLM plays an important role in central regulation of arterial pressure and heart rate under both normotensive and hypertensive conditions. A greater reduction in MSAP in the AdeNOS-treated SHR further indicates a reduced action of NO at the RVLM in the pathogenesis of hypertension. (2) An excessive oxidative stress of a reduced function of SOD2 in RVLM may be an important factor in neural mechanism of hypertension in SHR. The same mechanism, at the same time, may underlie the rebound hypertensive observed in the AdeNOS-treated SHR. (3) The excessive oxidative stress in the RVLM contributes to hypertension by at least two mechanisms. One is to cause oxidative injury in the RVLM and the other is to interact with NO to decrease already insufficient activity of NO in central cardiovascular regulation.